)
)
Medicure Investor Relations Material
Latest events
Q3 2024
Medicure
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Medicure Inc
Access all reports
Medicure Inc. researches develops and commercializes human therapies for the cardiovascular market in the US. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. The company also sells UCERIS rectal foam for the induction of remission in patients with mild to moderate active distal ulcerative colitis, as well as develops deforolimus injection for acute myelogenous leukemia; roxadustat for anemia in chronic kidney disease; Apadenoson that is in Phase III clinical trials to diagnose coronary artery anomalies; and MC-4232, an oral endothelial receptor antagonist that is in Phase IIb clinical trial to treat congestive heart failure.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
MPH
Country
🇨🇦 Canada